← FUJIFILM overview

FUJIFILM vs Integer: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

FUJIFILM Holdings Corp (4901.JP)

Q3 2026
▲2▼1

Fujifilm's mixed quarter: record sales but profit hit; printer spin-off weighed

  • Q1 profit drops 30% on Bio CDMO costs and restructuring Fujifilm's first-quarter net income fell 30% to ¥37.4 billion even as revenue hit a record ¥826.5 billion. Higher fixed costs in the Bio CDMO business, one-time restructuring charges at Business Innovation, and rising raw material prices squeezed operating profit, and the Healthcare segment swung to a loss. Management cut its full-year Healthcare profit guidance, a clear drag on the stock.

    This is the single biggest new financial event for 4901.JP, directly explaining why earnings and guidance disappointed.

  • Printer business spin-off considered within 2-3 years Fujifilm said it is considering spinning off Fujifilm Business Innovation, its office printer and multifunction device unit, in two to three years and listing it separately. That unit is about 35% of total revenue. A spin-off could unlock value by letting each business focus, but it also shrinks the parent's revenue base and adds uncertainty while details are vague.

    This is a major new strategic move that changes the company's structure and is a key reason investors are reassessing 4901.JP.

  • Nvidia partnership brings AI-powered medical CT systems At Nvidia's Japan AI event, Fujifilm introduced next-generation CT scanners built with Nvidia technology. This ties Fujifilm's medical imaging business to the fast-growing AI healthcare trend, supporting future product demand and reinforcing its technology credentials. The financial impact is not immediate, but it strengthens the long-term growth story for the Healthcare segment.

    It is a new collaboration that supports the investment case for Fujifilm's healthcare and technology businesses.

  • Film camera revival and Google Photos print store expand imaging demand Fujifilm's Utsurundesu disposable camera is seeing renewed popularity, with new waterproof and black-and-white models launching in August. Separately, Fujifilm launched a print store integrated with Google Photos in the U.S., managing the storefront and expanding photo products. Both point to fresh demand in the Imaging segment, a smaller but profitable and brand-building part of the company.

    These are new demand-side developments that show growth in Fujifilm's consumer imaging business.

August 2026
▲2▼1

Fujifilm's mixed quarter: record sales but profit hit; printer spin-off weighed

  • Q1 profit drops 30% on Bio CDMO costs and restructuring Fujifilm's first-quarter net income fell 30% to ¥37.4 billion even as revenue hit a record ¥826.5 billion. Higher fixed costs in the Bio CDMO business, one-time restructuring charges at Business Innovation, and rising raw material prices squeezed operating profit, and the Healthcare segment swung to a loss. Management cut its full-year Healthcare profit guidance, a clear drag on the stock.

    This is the single biggest new financial event for 4901.JP, directly explaining why earnings and guidance disappointed.

  • Printer business spin-off considered within 2-3 years Fujifilm said it is considering spinning off Fujifilm Business Innovation, its office printer and multifunction device unit, in two to three years and listing it separately. That unit is about 35% of total revenue. A spin-off could unlock value by letting each business focus, but it also shrinks the parent's revenue base and adds uncertainty while details are vague.

    This is a major new strategic move that changes the company's structure and is a key reason investors are reassessing 4901.JP.

  • Nvidia partnership brings AI-powered medical CT systems At Nvidia's Japan AI event, Fujifilm introduced next-generation CT scanners built with Nvidia technology. This ties Fujifilm's medical imaging business to the fast-growing AI healthcare trend, supporting future product demand and reinforcing its technology credentials. The financial impact is not immediate, but it strengthens the long-term growth story for the Healthcare segment.

    It is a new collaboration that supports the investment case for Fujifilm's healthcare and technology businesses.

  • Film camera revival and Google Photos print store expand imaging demand Fujifilm's Utsurundesu disposable camera is seeing renewed popularity, with new waterproof and black-and-white models launching in August. Separately, Fujifilm launched a print store integrated with Google Photos in the U.S., managing the storefront and expanding photo products. Both point to fresh demand in the Imaging segment, a smaller but profitable and brand-building part of the company.

    These are new demand-side developments that show growth in Fujifilm's consumer imaging business.

Latest
▲2▼1

Fujifilm's mixed quarter: record sales but profit hit; printer spin-off weighed

  • Q1 profit drops 30% on Bio CDMO costs and restructuring Fujifilm's first-quarter net income fell 30% to ¥37.4 billion even as revenue hit a record ¥826.5 billion. Higher fixed costs in the Bio CDMO business, one-time restructuring charges at Business Innovation, and rising raw material prices squeezed operating profit, and the Healthcare segment swung to a loss. Management cut its full-year Healthcare profit guidance, a clear drag on the stock.

    This is the single biggest new financial event for 4901.JP, directly explaining why earnings and guidance disappointed.

  • Printer business spin-off considered within 2-3 years Fujifilm said it is considering spinning off Fujifilm Business Innovation, its office printer and multifunction device unit, in two to three years and listing it separately. That unit is about 35% of total revenue. A spin-off could unlock value by letting each business focus, but it also shrinks the parent's revenue base and adds uncertainty while details are vague.

    This is a major new strategic move that changes the company's structure and is a key reason investors are reassessing 4901.JP.

  • Nvidia partnership brings AI-powered medical CT systems At Nvidia's Japan AI event, Fujifilm introduced next-generation CT scanners built with Nvidia technology. This ties Fujifilm's medical imaging business to the fast-growing AI healthcare trend, supporting future product demand and reinforcing its technology credentials. The financial impact is not immediate, but it strengthens the long-term growth story for the Healthcare segment.

    It is a new collaboration that supports the investment case for Fujifilm's healthcare and technology businesses.

  • Film camera revival and Google Photos print store expand imaging demand Fujifilm's Utsurundesu disposable camera is seeing renewed popularity, with new waterproof and black-and-white models launching in August. Separately, Fujifilm launched a print store integrated with Google Photos in the U.S., managing the storefront and expanding photo products. Both point to fresh demand in the Imaging segment, a smaller but profitable and brand-building part of the company.

    These are new demand-side developments that show growth in Fujifilm's consumer imaging business.

Integer Holdings Corp (ITGR)

Q3 2026
▲1▼1

KKR's $127/share buyout drives ITGR, with approval risk remaining

  • KKR buyout at $127 per share KKR agreed to buy Integer for $127 per share in cash, a $5.7 billion deal at a 51.8% premium. The stock now trades near the offer, so price reflects the deal, not company performance.

    This is the dominant new event that now defines ITGR's stock price.

  • Deal approval still pending Financing is secured, but the deal still needs shareholder and regulatory approval. Analysts downgraded to neutral, and fair-value estimates of $112–$139 sit around the offer, showing limited upside unless a higher bid emerges.

    It explains the main remaining risks and why the stock trades near the offer.

  • Weak Q2 results and withdrawn guidance Q2 profit fell to $23.6 million from $37 million, revenue slipped 2.6%, and gross margin narrowed to 24.3%. Management withdrew guidance and canceled its earnings call, removing forward-looking data for investors.

    It is the key counterweight showing underlying business weakness behind the deal.

  • Investor-rights review may seek higher bid An investor-rights law firm is reviewing whether $127 is fair and may seek a higher bid. This creates a small chance of a bump, but also adds uncertainty around the deal's final price.

    It highlights a potential upside catalyst and a source of deal uncertainty.

August 2026
▲1▼1

KKR's $127 Cash Buyout Sets ITGR's Price, Despite Weak Q2

  • KKR buyout locks in $127 cash per share Integer agreed to be bought by KKR for $127 per share in cash, a $5.7 billion deal. That price now anchors the stock, because shareholders expect to receive it when the deal closes. The buyer already has financing, so the main remaining hurdles are a shareholder vote and regulatory approvals.

    The buyout is the single force now setting ITGR's price and the main answer to why it moves.

  • Weak Q2 profit and sales, margins squeezed Second-quarter profit fell to $23.61 million from $37.01 million, and revenue slipped 2.6% to $464.1 million. Gross margin shrank to 24.3% from 27.1%. This weak operating picture is a counterweight: it shows the business was softening even as the buyout price caps the stock.

    It is the main negative fundamental fact and the real counterweight to the buyout.

  • Company drops guidance and earnings call Integer withdrew its financial outlook and canceled its quarterly earnings call, saying merger progress now matters more than operating targets. For investors this removes forward-looking numbers, so the stock trades on deal news rather than company performance. It also signals management is focused on closing the KKR sale.

    It explains why ordinary operating news no longer drives the stock and why the deal dominates.

  • Law firm review may seek a higher price An investor-rights law firm is investigating whether the $127-per-share KKR sale is fair and may push for more money or extra disclosures. Such reviews are common in buyouts. If they lead to a raised bid, the stock could rise above $127; if not, they are mostly noise.

    It is the only new event that could change the deal price, so it matters to the buyout story.

Latest
▲1▼1

KKR's $127 Cash Buyout Sets ITGR's Price, Despite Weak Q2

  • KKR buyout locks in $127 cash per share Integer agreed to be bought by KKR for $127 per share in cash, a $5.7 billion deal. That price now anchors the stock, because shareholders expect to receive it when the deal closes. The buyer already has financing, so the main remaining hurdles are a shareholder vote and regulatory approvals.

    The buyout is the single force now setting ITGR's price and the main answer to why it moves.

  • Weak Q2 profit and sales, margins squeezed Second-quarter profit fell to $23.61 million from $37.01 million, and revenue slipped 2.6% to $464.1 million. Gross margin shrank to 24.3% from 27.1%. This weak operating picture is a counterweight: it shows the business was softening even as the buyout price caps the stock.

    It is the main negative fundamental fact and the real counterweight to the buyout.

  • Company drops guidance and earnings call Integer withdrew its financial outlook and canceled its quarterly earnings call, saying merger progress now matters more than operating targets. For investors this removes forward-looking numbers, so the stock trades on deal news rather than company performance. It also signals management is focused on closing the KKR sale.

    It explains why ordinary operating news no longer drives the stock and why the deal dominates.

  • Law firm review may seek a higher price An investor-rights law firm is investigating whether the $127-per-share KKR sale is fair and may push for more money or extra disclosures. Such reviews are common in buyouts. If they lead to a raised bid, the stock could rise above $127; if not, they are mostly noise.

    It is the only new event that could change the deal price, so it matters to the buyout story.

July 2026
▲2▼1

KKR's $127-a-share buyout deal is now the whole story for ITGR

  • KKR agrees to buy Integer for $127 a share KKR signed a definitive deal to take Integer private for $127 a share in cash, about $5.7 billion, a 51.8% premium to the price before the strategic review. The stock jumped toward the offer, and the deal is expected to close by year-end.

    This is the single new event that now sets ITGR's price, so it is the core answer.

  • No financing risk, but a vote and regulators must clear it The buyer needs no financing, so the main risks are stockholders approving the deal and regulators clearing it. If it closes, Integer leaves the New York Stock Exchange and becomes privately held, so the shares stop trading publicly.

    Explains the real conditions and counterweight behind the agreed deal, which readers need to judge it.

  • Analysts cut ratings; fair-value estimates still sit below the offer After the deal, analysts downgraded the stock to neutral, saying further gains depend on the deal closing. One fair-value estimate rose to $112.14, still under the $127 offer, while another model says $139. This shows the price is now pinned near the deal terms, not company performance.

    Gives the honest counterweight: upside is limited and tied to completion, not to the business.

  • Insurance-driven procedure slowdown is now a side issue An Intuitive Surgical warning that insurance changes could slow U.S. procedures briefly dragged medical device stocks down, including Integer. With the buyout agreed, this demand worry matters far less to the price than the deal itself.

    It is the only negative force this period, but the buyout has largely overtaken it.

▲2▼1

KKR's $127-a-share buyout deal is now the whole story for ITGR

  • KKR agrees to buy Integer for $127 a share KKR signed a definitive deal to take Integer private for $127 a share in cash, about $5.7 billion, a 51.8% premium to the price before the strategic review. The stock jumped toward the offer, and the deal is expected to close by year-end.

    This is the single new event that now sets ITGR's price, so it is the core answer.

  • No financing risk, but a vote and regulators must clear it The buyer needs no financing, so the main risks are stockholders approving the deal and regulators clearing it. If it closes, Integer leaves the New York Stock Exchange and becomes privately held, so the shares stop trading publicly.

    Explains the real conditions and counterweight behind the agreed deal, which readers need to judge it.

  • Analysts cut ratings; fair-value estimates still sit below the offer After the deal, analysts downgraded the stock to neutral, saying further gains depend on the deal closing. One fair-value estimate rose to $112.14, still under the $127 offer, while another model says $139. This shows the price is now pinned near the deal terms, not company performance.

    Gives the honest counterweight: upside is limited and tied to completion, not to the business.

  • Insurance-driven procedure slowdown is now a side issue An Intuitive Surgical warning that insurance changes could slow U.S. procedures briefly dragged medical device stocks down, including Integer. With the buyout agreed, this demand worry matters far less to the price than the deal itself.

    It is the only negative force this period, but the buyout has largely overtaken it.